KN
KNBIF.US Kane Biotech Inc
- Market cap
- USD 4.80M
- P/E
- -
- P/B
- 102.61x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is KNBIF.US undervalued?
Graham numberThe Graham number of Kane Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kane Biotech Inc fundamental analysis
No fundamental analysis for Kane Biotech Inc yet.
Kane Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for trea…
Full company profileKane Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kane Biotech Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 245K | 1.04M | 506K | 1.69M | 1.34M | 1.61M | 2.67M | 149K | 2.08M | 428K | 103K |
| Gross Profit | 121K | 913K | 115K | 610K | 527K | 568K | 1.41M | 109K | 872K | -163K | -69.1K |
| Operating Income | -2.43M | -2.69M | -3.18M | -3.59M | -4.22M | -4.88M | -3.46M | -3.36M | -3.92M | -3.11M | -2.94M |
| EBITDA | -2.39M | -3.18M | -3.10M | -764K | -3.65M | -4.25M | -2.95M | -3.11M | -3.71M | -2.95M | -2.87M |
| Net Income | -2.55M | -2.79M | -3.26M | -960K | -3.72M | -4.60M | -3.89M | -5.03M | 6.10M | -2.72M | -3.10M |
| EPS | -0.07 | -0.05 | -0.04 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | 0.05 | -0.02 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 2.13M | 3.40M | 1.56M | 2.76M | 5.04M | 6.13M | 5.62M | 5.68M | 2.49M | 2.73M | 2.23M |
| Total Liabilities | 784K | 659K | 2.54M | 1.92M | 3.96M | 7.70M | 9.76M | 14.1M | 4.12M | 3.48M | 3.22M |
| Shareholders' Equity | 1.35M | 2.74M | -985K | 837K | -1.49M | -3.89M | -6.52M | -10.6M | -1.63M | -746K | -994K |
| Cash & Short-term Investments | 740K | 1.98M | 75.4K | 834K | 1.01M | 1.15M | 1.10M | 749K | 359K | 901K | 855K |
| Total Debt | 480K | - | 500K | 170K | 2.25M | 4.71M | 6.86M | 9.26M | 2.18M | 2.30M | 1.96M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.36M | -2.04M | -2.85M | -955K | -3.94M | -2.29M | -3.04M | -3.22M | -4.11M | -3.25M | -2.24M |
| Capital Expenditure | 266K | 230K | 146K | 97.4K | 126K | 354K | 87.5K | 9.22K | 90.1K | 4.89K | 90.3K |
| Free Cash Flow | -2.63M | -2.27M | -3.00M | -1.05M | -4.07M | -2.64M | -3.13M | -3.23M | -4.20M | -3.26M | -2.24M |
| Ratios | |||||||||||
| ROE | -189.1% | -101.8% | - | -114.7% | - | - | - | - | - | - | - |
| ROA | -119.6% | -82.0% | -209.6% | -34.8% | -73.8% | -75.1% | -69.2% | -88.6% | 244.5% | -99.5% | -139.1% |
| Net Profit Margin | -1,041.3% | -269.1% | -644.1% | -56.7% | -277.0% | -286.4% | -145.8% | -3,379.0% | 293.0% | -636.0% | -3,012.5% |
| Debt to Equity | 0.36x | - | - | 0.20x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kane Biotech Inc dividends
Kane Biotech Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Mar 13, 2017.
Who owns Kane Biotech Inc
- Insiders 39.82%
- Institutions 0.00%
- Public & others 60.18%
- Shares outstanding 205M
- Free float 114M
Kane Biotech Inc company profile
- Company name
- Kane Biotech Inc
- Ticker
- KNBIF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 290-100 Innovation Drive, Winnipeg, MB, Canada, R3T 6G2
- Phone
- 204-453-1301
- Website
- kanebiotech.com
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers scalp detoxifier product line under the Omni Bioceuticals brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate acne vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Kane Biotech Inc management
4- Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNCInterim CEO, Director & Member of Scientific Advisory Board · born 1965
- Mr. Ray DupuisChief Financial Officer
- Dr. Gregory S. Schultz Ph.D.Chief Scientific Officer & Member of Scientific Advisory Board · born 1950
- Lorne GorberInvestor Relations